Coloplast’s FY 2024/25 financial guidance1 of organic revenue growth at 8-9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment. This ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Coloplast's current valuation doesn't offer a compelling risk/reward trade-off today, despite high-quality growth potential.

Danish Coloplast, a healthcare company developing medical products and services, wanted to create such a stand for the 2018 EWMA expo in Krakow, Poland. The company envisioned a coherent universe, ...